United States: What buy-side directors need to know

Author: | Published: 5 Apr 2005
Email a friend

To include more than one recipient, please seperate each email address with a semi-colon ';'

Uncounted reams have been devoted to descriptions of duties of directors of US target companies in the context of M&A transactions. Interest in this topic endures for two main reasons. First, the issues are complex: the standards applicable to target boards have proliferated, kudzu-like, so that any of five different legal standards might be used to test a decision of a Delaware target's board, depending on the circumstances. Second, the stakes are high: the decision to sell a company is one a target board typically gets to make only once, and target shareholders, who are deeply interested in the result, have not been shy about complaining if they feel the decision was mishandled.

What about the decisions of boards of acquiring companies? Are the issues less complex for boards thinking about buying, rather than selling, a company? Do shareholders of acquiring companies care less about the outcome?

If it ever was safe to answer yes to these questions, today's increasing scrutiny of board decision-making processes makes it risky for directors to adopt a casual attitude towards buying other companies.

The business judgment rule

US courts have traditionally deferred to the business judgment of directors if they act in good faith, with loyalty to the corporation, and on an informed basis. The presumption that director actions satisfy these requirements is known as the business judgment rule. As the Delaware Supreme Court put it in Brehm v Eisner, a 2000 case involving Disney's large severance payment to Michael Ovitz, "Courts do not measure, weigh or quantify directors' judgments. We do not even decide if they are reasonable in this context. Due care in the decision-making context is process due care only. Irrationality is the outer limit of the business judgment rule."

In most cases, the business judgment rule will apply to a board's decision to acquire another company. Courts will not second-guess the informed decision of a disinterested board to approve an acquisition - even if that acquisition turns out badly. The heightened levels of scrutiny courts have applied to target boards - the Revlon test of whether the board has sought the highest price reasonably available in a change of control context; the Unocal test as to whether defensive actions are reasonable in relation to a reasonably perceived threat; the Blasius test as to whether actions that interfere with shareholder voting are undertaken with a compelling justification; and the entire fairness test applicable to going private transactions with controlling shareholders - have not typically been applied to boards of acquiring companies. That is largely because courts have perceived there to be a conflict of interests on the part of target boards, which may come from their desire to remain in office, or because of their ties to target management who may be displaced in a transaction, but which is not usually present when the director is on the buy side.

Moreover, Delaware, and most other states, have adopted laws permitting corporate charters to limit directors' personal liability for breach of the duty of care - with exceptions. Delaware, for instance, does not allow a corporation to limit a director's liability for "acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law."

Does the existence of the business judgment rule, coupled with exculpatory charter provisions, mean that non-conflicted directors of acquiring companies can exhale?

Not necessarily. On January 12 2005 - the sixth anniversary of McKesson Corporation's merger with HBO & Company - McKesson agreed to pay $960 million to settle securities class action litigation arising from HBOC's restatement of earnings as a result of improperly recorded revenues. In a single day, McKesson lost over $9 billion in market value when it first disclosed, less than four months after the closing, that HBOC had overstated earnings. While McKesson has settled with the class action plaintiffs, the settlement does not cover pending claims that McKesson's directors breached their duties by not discovering HBOC's fraud.

McKesson's directors have the benefit of an exculpatory charter provision, but in Ash v McCall, a 2000 Delaware chancery court decision that dismissed without prejudice claims that the McKesson board breached its fiduciary duties by approving the HBOC deal, the court made clear that litigation against the McKesson directors could proceed if plaintiffs are able to allege particular facts demonstrating bad faith on the part of directors - including facts indicating that the directors "had actual knowledge of accounting irregularities, or knowledge of facts indicating potential accounting irregularities, and took no action..."

Another example of an acquisition with ruinous consequences: just four months after the merger of CUC International and HFS to form Cendant Corporation, Cendant announced that management had discovered accounting irregularities at CUC - causing Cendant's market capitalization to drop by $14 billion in a single day. Cendant ended up settling the ensuing litigation for over $2.8 billion.

While these examples have not to date resulted in personal liability for directors, the recent Enron and WorldCom settlements, in which directors agreed to pay millions of dollars toward settlement funds (although the WorldCom settlement later failed to win court approval), are sobering reminders that directors may face personal risk for serious failures of oversight.

The duty of good faith

Recent Delaware case law has made clear that directors can be held personally liable, even if their companies' charters exculpate them from liability for duty of care violations, if their conduct is found to be sufficiently egregious.

For example, in the most recent chancery court decision arising from Disney's severance payments to Michael Ovitz, chancellor Chandler said the facts alleged did not implicate merely negligence or gross negligence, but instead suggested that the directors had not "exercised any business judgment or made any good faith attempt to fulfill the fiduciary duties they owed to Disney and its shareholders." According to the court, the alleged facts suggest the defendant directors "consciously and intentionally disregarded their responsibilities" - meaning, if true, that "the directors' actions are either not in good faith or involve intentional misconduct."

In the Abbot Laboratories case, the Seventh Circuit, applying Illinois law similar to Delaware's, held to be legally enough allegations that Abbott Laboratories directors knew of significant problems (repeated notices of FDA rule violations) but took no action. The allegations, if proved, showed a "systematic failure of the board to exercise oversight." To the court, six years' noncompliance resulting in the FDA's largest civil fine "indicate that the directors' decision to not act was not made in good faith," and the claims were not precluded by a charter liability limitation.

In the Emerging Communications case, which involved a going private transaction at a price the court found to be only about 27% of the company's actual value, an outside director was found jointly and severally liable for money damages for voting to approve the transaction "even though he knew, or at the very least had strong reasons to believe, that the...merger price was unfair."

Why was the director not protected by the company's exculpatory charter provision? The court held the director had breached his duty of loyalty and/or good faith, making him ineligible for exculpation. Why was he not protected in relying on the special committee that approved the transaction, or on the investment banker that opined that the price was fair? The court does not address this question squarely, but the answer is the same: directors are fully protected in relying on committees, management and carefully chosen experts as to matters within their expert competence - but only if that reliance is in good faith.

While these cases do not specifically address duties of buy-side directors, it is not hard to see how the legal theories used in these cases, which lead to personal liability for directors, can also apply in the acquisition context. Directors necessarily delegate much of the work in an acquisition to company management and to outside experts. In most cases they will be fully protected in doing so. But if directors fail to inform themselves of a large acquisition that leads to post-closing problems, the business judgment rule will not protect them. Similarly, if directors actually know there is something wrong with the target, or that the company is overpaying, they cannot close their eyes to the problem and rely blindly on the assurances of management or outside advisers. It is unfortunate, but nevertheless true, that directors' actions tend to be judged with the benefit of hindsight. This is especially troubling when courts apply inherently imprecise standards, such as inquiring as to whether directors have acted in good faith, at a time when the transaction has proven to have been a mistake.

Am I buying or selling?

Directors of acquiring companies must be mindful that in stock-for-stock transactions, they are selling part of their own company as well as buying another company. Sometimes in these circumstances, particularly when acquiring company shareholder approval will be required for the transaction, acquiring company boards are asked to bless voting lock-ups, no-shop provisions and other deal protection devices. The decision to approve measures intended to protect the deal may be subject to greater judicial scrutiny than the decision to enter into the deal itself. Directors should understand how the deal protection provisions work, and should consider whether they are reasonable and whether they will have the effect of limiting their ability to exercise their fiduciary duties in the future. Directors should also be alert to factors that have led courts to perceive that directors have a conflict of interests - for example, in a large acquisition, if some of the buyer's directors will no longer serve as directors of the combined company.

Staying out of trouble

Here are some things directors and their advisers should keep in mind to help reduce the chance that a court will second-guess a board's decision to acquire another company:

Make decisions. The business judgment rule protects decisions of the board, not failures to make decisions. That means that significant acquisitions should be reviewed by the board. If the board has a policy of delegating to management responsibility for acquisitions below a specified threshold, it should make sure it has a process in place to ensure that those acquisitions do not involve risks extending beyond that threshold.

Stay informed. Directors should understand the transaction, including potential risks that arise through the due diligence process. Failing to tell the directors about potential risks does not help them show that they exercised informed business judgment - which can include taking risks. Directors should also understand the workings of any deal protection devices applicable to the acquiring company.

Have a good process. For large acquisitions, it is helpful to have multiple board meetings - so that directors have ample opportunity to ask questions, and so that their concerns can be addressed in the deal terms.

Make effective use of experts. Under the law of Delaware and most other states, directors are fully protected in relying in good faith on reports and opinions of management, committees and carefully chosen experts as to matters within their expertise.

Author biography

William D Regner

Debevoise & Plimpton LLP

William D Regner is a partner in the New York office of Debevoise & Plimpton LLP. His practice focuses primarily on mergers and acquisitions, including public company and cross-border transactions, as well as investment management, corporate and securities law matters.

William Regner has played a key role in numerous M&A matters for the firm, including Verizon Communications' pending acquisition of MCI. He regularly represents prominent investment banking firms in their role as financial adviser in major transactions. He worked on the Chrysler-DaimlerBenz merger, the Phelps Dodge double unsolicited exchange offer, and handles many of the firm's M&A assignments in the asset management sector.

William Regner is the co-author of Takeovers: A Strategic Guide to Mergers & Acquisitions (Aspen Law & Business 2004) and has written numerous articles on mergers and acquisitions and corporate law matters.


Debevoise & Plimpton LLP
919 Third Avenue
New York, NY 10022
Tel: +1 212 909 6000
Fax: +1 212 909 6836
Web: www.debevoise.com

Upcoming events